Vaxcyte, Inc. $PCVX Shares Purchased by Eventide Asset Management LLC

Eventide Asset Management LLC grew its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 141.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 917,115 shares of the company’s stock after acquiring an additional 537,785 shares during the quarter. Eventide Asset Management LLC’s holdings in Vaxcyte were worth $42,313,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the stock. Maverick Capital Ltd. increased its holdings in shares of Vaxcyte by 5.0% during the fourth quarter. Maverick Capital Ltd. now owns 1,354,237 shares of the company’s stock valued at $62,484,000 after acquiring an additional 64,670 shares in the last quarter. CANADA LIFE ASSURANCE Co increased its holdings in shares of Vaxcyte by 17.9% during the fourth quarter. CANADA LIFE ASSURANCE Co now owns 13,403 shares of the company’s stock valued at $619,000 after acquiring an additional 2,039 shares in the last quarter. Segall Bryant & Hamill LLC increased its holdings in shares of Vaxcyte by 4.7% during the fourth quarter. Segall Bryant & Hamill LLC now owns 193,423 shares of the company’s stock valued at $8,925,000 after acquiring an additional 8,628 shares in the last quarter. Walleye Capital LLC acquired a new position in shares of Vaxcyte during the fourth quarter valued at about $683,000. Finally, Quarry LP acquired a new position in shares of Vaxcyte during the fourth quarter valued at about $231,000. Institutional investors and hedge funds own 96.78% of the company’s stock.

Insider Buying and Selling at Vaxcyte

In related news, CAO Elvia Cowan sold 3,000 shares of the stock in a transaction on Tuesday, April 7th. The stock was sold at an average price of $60.00, for a total value of $180,000.00. Following the completion of the transaction, the chief accounting officer directly owned 28,975 shares of the company’s stock, valued at approximately $1,738,500. This represents a 9.38% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Jim Wassil sold 2,250 shares of the stock in a transaction on Monday, June 1st. The shares were sold at an average price of $49.52, for a total value of $111,420.00. Following the completion of the transaction, the chief operating officer directly owned 158,494 shares of the company’s stock, valued at approximately $7,848,622.88. This represents a 1.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 9,392 shares of company stock valued at $524,426. 3.30% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

PCVX has been the topic of several recent research reports. Wall Street Zen lowered Vaxcyte from a “sell” rating to a “strong sell” rating in a research report on Tuesday, April 28th. Jefferies Financial Group restated a “buy” rating on shares of Vaxcyte in a research report on Tuesday, March 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vaxcyte in a research report on Wednesday, April 8th. Finally, BTIG Research increased their target price on Vaxcyte from $85.00 to $89.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $86.00.

Vaxcyte Price Performance

Shares of NASDAQ:PCVX opened at $47.46 on Friday. Vaxcyte, Inc. has a 1 year low of $29.08 and a 1 year high of $65.00. The firm has a market capitalization of $6.85 billion, a price-to-earnings ratio of -6.90 and a beta of 1.24. The business’s 50 day moving average price is $54.28 and its 200-day moving average price is $52.66.

Vaxcyte (NASDAQ:PCVX) last announced its earnings results on Wednesday, May 6th. The company reported ($2.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.74) by ($0.56). During the same quarter in the previous year, the firm posted ($1.04) earnings per share. On average, sell-side analysts expect that Vaxcyte, Inc. will post -7.56 earnings per share for the current year.

Vaxcyte Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.